国际皮肤性病学杂志    2006 32 (6): 343-345   ISSN: 2096-5540  CN: 32-1880/R   皮肤型红斑狼疮的治疗现状 刘春, 张国毅, 王千秋 中国医学科学院、中国协和医科大学皮肤病研究所, 南京210042 收稿日期 2006-04-26  修回日期 null  网络版发布日期 null 参考文献  [1] Callen JP.Management of "refractory" skin disease in patients with lupus erythematosus.Best Pract Res Clin Rheumatol,2005,19:767-784. [2] Lampropoulos CE,Sangle S,Harrison P,et al.Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus:a possible alternative.Rheumatology (Oxford),2004,43:1383-1385. [3] Tlacuilo-Parra A,Guevara-Gutierrez E,Gutierrez-Murillo F,et al.Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus.Rheumatology (Oxford),2005,44:1564-1568. [4] Fabbri P,Cardinali C,Giomi B,et al.Cutaneous lupus erythematosus:diagnosis and management.Am J Clin Dermatol,2003,4:449-465. [5] Wozniacka A,McCauliffe DP.Optimal use of antimalarials in treating cutaneous lupus erythematosus.Am J Clin Dermatol,2005,6:1-11. [6] Wallace DJ.Antimalarials-the 'real' advance in lupus.Lupus,2001,10:385-387. [7] Kuhn A,Richter-Hintz D,Oslislo C,et al.Lupus erythematosus tumidus-a neglected subset of cutaneous Lupus erythematosus:report of 40 cases.Arch Dermatol,2000,136:1033-1041. [8] McCauliffe DP.Cutaneous lupus erythematosus.Semin Cutan Med Surg,2001,20:14-26. [9] Al-Mutairi N,Rijhwani M,Nour-Eldin O.Hypertrophic lupus erythematosus treated successfully with acitretin as monotherapy.J Dermatol,2005,32:482-486. [10] Neri R,Mosca M,Bernacchi E,et al.A case of SLE with acute,subacute and chronic cutaneous lesions successfully treated with Dapsone.Lupus,1999,8:240-243. [11] Wenzel J,Brahler S,Bauer R,et al.Efficacy and safety ofmethotrexate in recalcitrant cutaneous lupus erythematosus:results of a retrospective study in 43 patients.Br J Dermatol,2005,153:157. [12] Schanz S,Ulmer A,Rassner G,et al.Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil.Br J Dermatol,2002,147:174-178. [13] Pisoni CN,Obermoser G,Cuadrado MJ,et al.Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities:poor results with mycophenolate mofetil.Clin Exp Rheumatol,2005,23:393-396. [14] Goodfield M,Davison K,Bowden K.Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE).J Dermatolog Treat,2004,15:46-50. [15] Housman TS,Jorizzo JL,McCarty MA,et al.Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus.Arch Dermatol,2003,139:50-54. [16] Cuadrado MJ,Karim Y,Sanna G,et al.Thalidomide for the treatment of resistant cutaneous lupus:efficacy and safety of different therapeutic regimens.Am J Med,2005,118:246-250. [17] Wu JJ,Huang DB,Pang KR,et al.Thalidomide:dermatological indications,mechanisms of action and side-effects.Br J Dermatol,2005,153:254-273. [18] Briani C,Zara G,Rondinone R,et al.Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus.Autoimmunity,2005,38:549-555. [19] Bastuji-Garin S,Ochonisky S,Bouche P,et al.Incidence and risk factors for thalidomide neuropathy:a prospective study of 135 dermatologic patients.J Invest Dermatol,2002,119:1020-1026. [20] Baniandres O,Boixeda P,Belmar P,et al.Treatment of lupus erythematosus with pulsed dye laser.Lasers Surg Med,2003,32:327-330. [21] Millard TP,Hawk JL.Ultraviolet therapy in lupus.Lupus,2001,10:185-187. 通讯作者: